Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized crossover pharmacokinetic and pharmacodynamic study of RP103 vs immediate-release cysteamine in cystinosis
2009-017882-42Phase 3Completed
- Sponsor
- Raptor Pharma
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cysteamine in cystinosis (2 arms), sponsored by Raptor Pharma. Primary endpoints: Primary: Comparable depletion of steady-state cysteamine-trough WBC cystine and Primary: Safety and tolerability of RP103. Started Jun 2010; status: completed.
02
Drugs
cysteamine
03
Conditions
cystinosis
Beyond the preview
Go deeper on 2009-017882-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017882-42.